“We are pleased to add NXT-Dx’s expertise to our growing epigenomics services platform,” Didier Allaer, CEO of Diagenode, said. “The services offered by NXT-Dx perfectly complement Diagenode’s current chromatin, RNA and DNA methylation assay services and will allow researchers to focus both on discovery and validation of epigenetic signatures.”
the acquisition of NXT-Dx’s services will provide Diagenode researches access to easier screening of large patient populations to develop DNA methylation signatures and will broaden its role in the epigenetic biomarker industry.
“We are excited to be enhancing Diagenode’s service portfolio via this acquisition of our complementary services,” Maarten Braspenning, CEO of NXT-Dx, said. “With the combined expertise, we can now offer full end-to-end services for IVD screening of biomarkers and clinical validation of DNA methylation signatures.”